Periodic Reporting for period 1 - BRAINHIB (Integrated drug discovery approach to generate brain-penetrant inhibitors of glioblastoma cell proliferation)

Glioblastoma multiforme (GBM) is the most common and aggressive brain cancer. Without treatment the average survival following diagnosis is merely 3 months. Although clinically-approved kinase inhibitors present promising features to treat GBM, most of them do not cross the...